
7MM triple-negative breast cancer market eyes 4.7% CAGR growth until 2034
The sector’s expansion is attributed to rising incidence rates.
The triple-negative breast cancer (TNBC) market across the seven major markets (7MM) is expected to expand at a compound annual growth rate of 4.7% through 2034, according to a DelveInsight report.
The sector’s growth is attributed to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics, and greater investment in research and development.
“The launch of emerging therapies such as DATROWAY, PADCEV, BNT327/ PM8002, and others will fuel the TNBC market growth,” the report said.
However, the discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists may impede growth.
TNBC is the most difficult breast cancer subtype to manage due to its aggressive nature,” it added.
Lack of targeted treatment options, high rates of chemotherapy resistance, reduced treatment efficacy, and limited long-term remission further challenge the market.
7MM = US, Germany, France, Italy, Spain, UK, and Japan.